Driven by a commitment to innovation in regenerative aesthetics, PRODERMIS has developed 4L™ Technology — a next-generation formulation system that sets a new benchmark in product quality and performance. Each of the four Ls represents a pillar of the technology: Purity of raw materials, Performance through advanced molecular stabilization, Precision in particle structure and injection behavior, and Protection of skin health through biocompatibility.
With Polynucleotides, PRODERMIS isn’t just filling — it’s performing at a higher standard.
PRODERMIS Prosculpt fillers are engineered to deliver exceptional lift, integration, and longevity across a full spectrum of aesthetic indications. Each product in the range combines cross-linked Hyaluronic Acid with Polynucleotides (PN) using our proprietary 4L™ Technology, which ensures purity, stability, and seamless tissue adaptation.
This advanced formulation enhances rheological performance, offering practitioners superior control, smoother extrusion, and consistent results — even in complex treatment areas. Patients benefit from natural-looking volume, improved skin quality, and long-lasting definition, with reduced risk of swelling, migration, or irregularities.
At PRODERMIS, innovation is driven by science. Our R&D team works closely with medical professionals to continually optimise formulation performance and clinical outcomes. From particle engineering to biostimulatory integration, every detail of the Prosculpt range is informed by clinical feedback and laboratory excellence.
As global demand for non-surgical aesthetics continues to grow, PRODERMIS stands at the forefront of regenerative injectable science — offering next-generation solutions that redefine what’s possible with dermal fillers.
